Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
690
-
Total 13F shares, excl. options
-
246M
-
Shares change
-
+141K
-
Total reported value, excl. options
-
$41.6B
-
Value change
-
+$12.6M
-
Put/Call ratio
-
1.23
-
Number of buys
-
341
-
Number of sells
-
-296
-
Price
-
$169.42
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q3 2019
808 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q3 2019.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 690 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 246M shares
of 257M outstanding shares and own 95.71% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (26.3M shares), FMR LLC (24.7M shares), BlackRock Inc. (21.1M shares), VANGUARD GROUP INC (19.9M shares), STATE STREET CORP (11.3M shares), Capital World Investors (10.6M shares), WELLINGTON MANAGEMENT GROUP LLP (8.24M shares), JENNISON ASSOCIATES LLC (5.98M shares), RENAISSANCE TECHNOLOGIES LLC (5.8M shares), and ALLIANCEBERNSTEIN L.P. (5.78M shares).
This table shows the top 690 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.